Boston Scientific stock has had a rough run over the past year, yet the valuation checks point to a market price that still sits well below an internally estimated intrinsic value. For investors, that contrast between a depressed share chart and models that flag potential undervaluation is where the story starts.
- The share price has fallen 58.7% over the past 12 months, which puts Boston Scientific in clear reset territory in terms of market expectations.
- Future cash generation from the medical device portfolio can support the current price if execution stays on track. However, any setback in product adoption or pricing power would weigh quickly on what investors are willing to pay.
- The broader valuation checks lean cheap, with a high value score of 5, suggesting the stock screens as undervalued on most metrics used here.
The issue now is whether Boston Scientific's intrinsic value estimate and supporting metrics offer enough margin between price and fundamentals to interest investors after such a steep slide.
Compare Boston Scientific's reset with other potential value setups by scanning 33 high quality undervalued stocks, which also screen cheaply against their fundamentals.
Does Boston Scientific Look Undervalued on Cash Flow?
The Discounted Cash Flow model values Boston Scientific by projecting future free cash generation and then discounting those cash flows back to today. On the latest numbers, the business produced roughly $3.6b of free cash flow over the past twelve months, which gives the model a solid starting base rather than a turnaround story.
The projection set assumes growing cash flows rather than a shrinking profile and feeds into an estimated intrinsic value of about $85 per share. Against the current market price, that DCF outcome implies the stock trades at a 49.0% discount, so the cash flow stream supports a materially higher figure than the quote on screen.
Taken at face value, the Discounted Cash Flow workup indicates that Boston Scientific stock may be undervalued relative to the cash it is expected to generate.
Our Discounted Cash Flow (DCF) analysis suggests Boston Scientific is undervalued by 49.0%. Track this in your watchlist or portfolio, or discover 33 more high quality undervalued stocks.
Is Boston Scientific Still Cheap on Earnings?
The P/E ratio suits Boston Scientific because earnings remain the core anchor for how this medical equipment group is priced next to peers. On this measure, the stock trades at about 17.0x earnings, which is below the broader medical equipment sector on roughly 24.7x and also below the peer group on about 38.9x.
A more tailored lens is the modelled fair P/E ratio of roughly 29.9x. This reflects Boston Scientific's sector, size and risk profile rather than just a blunt industry average. The current 17.0x mark sits far under that fair level, so the market is assigning a sizeable discount relative to what this framework suggests could be justified on earnings power alone.
On this earnings multiple check, Boston Scientific stock appears undervalued compared with both its sector and the modelled fair P/E.
See what the numbers say about this price — find out in our valuation breakdown.
The Boston Scientific Narrative: What Would Justify Today's Price?
Narratives for Boston Scientific pick up where the valuation work leaves off by spelling out which paths for growth, margins and earnings would need to hold for the share price to be worth materially more or less than today. Each scenario ties a fair value estimate to a clear thesis about Boston Scientific's potential catalysts and key risks, so you can track over time which version of the story is actually unfolding on Simply Wall St's Community page.
One of the top community narratives on Boston Scientific: 56% undervalued
"The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons..."
Read one of the top narratives on Boston Scientific
Do you think there's more to the story for Boston Scientific? Head over to our Community to see what others are saying!
The Bottom Line
Boston Scientific appears undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple checks, which is an uncommon level of agreement across methods. The difference between those frameworks and the current quote largely comes down to whether cash generation, product adoption, and pricing can remain resilient enough to narrow that discount. For potential investors, the key question is whether the current markdown reflects an overly cautious market or a reasonable warning about execution risk in the medical device portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com